Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Leleu

Showing results (71-80 of 372) with videos related to

Pageof 38
Sort By:
Blood Advances|July 18, 2024
A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myelomaMeletios A Dimopoulos, Daniel Coriu, Sosana Delimpasi, et al.
American Journal of Hematology|May 13, 2016
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM)Xavier Leleu, Evangelos Terpos, Ramón García Sanz, et al.
Leukemia & Lymphoma|February 12, 2024
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparisonKatja Weisel, Meletios A Dimopoulos, Meral Beksac, et al.
Cancer Letters|June 17, 2008
Waldenstrom macroglobulinemiaXavier Leleu, Aldo M Roccaro, Anne-Sophie Moreau, et al.
Ejhaem|February 23, 2023
Real-world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and IsraelXavier Leleu, Eirini Katodritou, Thomas Kuehr, et al.
Blood Advances|February 9, 2021
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 studyEvangelos Terpos, Noopur Raje, Peter Croucher, et al.
Annals of Hematology|September 1, 2004
Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myelomaKhalil Kargar Samani, Michel Brazier, Claire Mathiot, et al.
Therapeutic Advances in Hematology|April 8, 2022
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairmentMeletios A Dimopoulos, Joseph Mikhael, Evangelos Terpos, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 14, 2025
Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR TrialKatja Weisel, Maria-Victoria Mateos, Ola Landgren, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 12, 2013
Genomic studies have identified multiple mechanisms of genetic changes in Waldenström macroglobulinemiaStéphanie Poulain, Charles Herbaux, Elisabeth Bertrand, et al.
Pageof 38

Showing results (71-80 of 372) with videos related to

Sort By:
Pageof 38
Blood Advances|July 18, 2024
A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myelomaMeletios A Dimopoulos, Daniel Coriu, Sosana Delimpasi, et al.
American Journal of Hematology|May 13, 2016
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM)Xavier Leleu, Evangelos Terpos, Ramón García Sanz, et al.
Leukemia & Lymphoma|February 12, 2024
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparisonKatja Weisel, Meletios A Dimopoulos, Meral Beksac, et al.
Cancer Letters|June 17, 2008
Waldenstrom macroglobulinemiaXavier Leleu, Aldo M Roccaro, Anne-Sophie Moreau, et al.
Ejhaem|February 23, 2023
Real-world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and IsraelXavier Leleu, Eirini Katodritou, Thomas Kuehr, et al.
Blood Advances|February 9, 2021
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 studyEvangelos Terpos, Noopur Raje, Peter Croucher, et al.
Annals of Hematology|September 1, 2004
Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myelomaKhalil Kargar Samani, Michel Brazier, Claire Mathiot, et al.
Therapeutic Advances in Hematology|April 8, 2022
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairmentMeletios A Dimopoulos, Joseph Mikhael, Evangelos Terpos, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 14, 2025
Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR TrialKatja Weisel, Maria-Victoria Mateos, Ola Landgren, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 12, 2013
Genomic studies have identified multiple mechanisms of genetic changes in Waldenström macroglobulinemiaStéphanie Poulain, Charles Herbaux, Elisabeth Bertrand, et al.
Pageof 38